NCT04251117 - GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects with Advanced HCC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 1, 2020

Primary Completion Date

November 29, 2024

Study Completion Date

November 29, 2028

Conditions

HCC

Interventions

BIOLOGICAL

GNOS-PV02

GNOS-PV02 delivered by intradermal injection and electroporation

BIOLOGICAL

INO-9012

INO-9012 delivered by intradermal injection and electroporation

DRUG

Pembrolizumab

Pembrolizumab administered as an intravenous (IV) infusion

DEVICE

CELLECTRA®2000 EP Device

CELLECTRA® 2000 Device is a system indicated for use to enhance the uptake and expression of plasmid-based biologics in order to enhance vaccine efficacy.

Trial Locations (3)

10029

Icahn School of Medicine at Mount Sinai, New York

21287

Johns Hopkins Hospital, Baltimore

Unknown

Auckland Clinical Studies, Auckland